Press Releases
2010
September
09/02/2010XOMA Regains NASDAQ Compliance
August
08/26/2010XOMA Appoints Jack L. Wyszomierski to Its Board of Directors
08/18/2010
XOMA Receives $4 Million for Sale of Royalty Interest in CIMZIA(R)
08/17/2010
XOMA Announces Reverse Stock Split
08/09/2010
XOMA Reports Second Quarter 2010 Financial Results
08/04/2010
XOMA 052 Designated Orphan Drug by FDA for Treatment of Behcet's Disease
08/02/2010
XOMA to Announce 2010 Second Quarter Financial Results and Host Webcast Conference Call on August 9, 2010
July
07/29/2010XOMA 052 Orphan Drug Designation for Behcet's Disease Recommended by European Medicines Agency
07/26/2010
XOMA Receives $750,000 Milestone Payment From AVEO Pharmaceuticals
07/23/2010
XOMA Enters Into $30 Million Committed Equity Financing Facility
June
06/30/2010XOMA Achieves Planned Enrollment Goal for Phase 2b Clinical Trial of XOMA 052 in Type 2 Diabetes
06/26/2010
Preclinical Results With XOMA 052 in Type 2 Diabetes Presented at American Diabetes Association 70th Scientific Sessions
06/22/2010
Journal Article in Endocrinology Highlights Preclinical XOMA 052 Data in Type 2 Diabetes
06/17/2010
Positive Clinical Findings Presented on XOMA 052 in Debilitating Eye Disease
06/15/2010
NASDAQ Grants XOMA's Request for Continued Listing
06/10/2010
XOMA to Host Conference Call to Present Initial Results From XOMA 052 Clinical Trial in Behcet's Disease
May
05/12/2010Abstract Published on Initial Results From XOMA 052 Clinical Trial in Behcet's Disease
05/06/2010
XOMA Reports First Quarter 2010 Financial Results
April
04/30/2010XOMA 052 Mechanism of Action Results Published in Journal of Biological Chemistry
04/29/2010
XOMA to Announce 2010 First Quarter Financial Results and Host Webcast Conference Call on May 6
04/19/2010
XOMA 052 Shows Potent In Vitro Inhibition of Interleukin-6 Production in Human Myeloma Cells
04/15/2010
XOMA Receives $1 Million Milestone Payment From Takeda Pharmaceutical
04/13/2010
XOMA Issued Two New U.S. Patents for Methods of Treating Type 2 Diabetes and Inflammatory Diseases Using Interleukin-1 Beta Antibodies
04/09/2010
Data on XOMA 052 to be Presented at the American Association of Cancer Research Annual Meeting
March
03/16/2010XOMA Receives Anticipated Notice of Non-Compliance From NASDAQ
03/14/2010
XOMA 052 Prevents Adverse Cardiac Remodeling in Animal Model of Heart Attack
03/12/2010
XOMA 052 Phase 2 Trial Initiated in Type 1 Diabetes Patients
03/11/2010
XOMA Reports 2009 and Fourth Quarter Financial Results
03/04/2010
XOMA to Announce 2009 and Fourth Quarter Financial Results and Host Conference Call on March 11
February
02/25/2010XOMA to Webcast Presentations From Two March 2010 Investment Conferences
02/09/2010
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
02/03/2010
XOMA Announces Presentation at BIO CEO and Investor Conference on February 9
02/02/2010
XOMA Announces $21 Million Underwritten Offering of Common Shares and Warrants
January
01/19/2010XOMA Reviews Priorities for 2010 and 2009 Accomplishments
2009
December
12/22/2009XOMA Reports Removal of "Going Concern" Qualification
12/10/2009
XOMA Presents Advantages of Its Multiple Antibody Formulation Technologies at Antibody Engineering Conference
12/09/2009
XOMA Announces NASDAQ Matter Resolved With Letter of Reprimand
November
11/19/2009XOMA Receives NASDAQ Determination Letter
11/17/2009
XOMA Appoints Jim Neal Vice President of Business Development
11/12/2009
XOMA 052 Selected as a Top Ten Project to Watch
11/11/2009
XOMA Announces Presentation at Lazard Healthcare Conference on November 18
11/09/2009
XOMA Reports 2009 Third Quarter Financial Results
11/06/2009
XOMA Expands Development Strategy for XOMA 052 to Include Cardiovascular Diseases
11/04/2009
Phase 2 Trial of XOMA 052 to be Initiated in Type 1 Diabetes Patients
11/04/2009
XOMA Granted First European Patent Covering XOMA 052
11/03/2009
XOMA to Announce Third Quarter 2009 Financial Results and Host Conference Call on November 9
11/03/2009
XOMA Signs Antibody Discovery Collaboration With Kaketsuken
October
10/20/2009XOMA Presents First XOMA 052 Cardiovascular Disease Animal Model Results
10/14/2009
XOMA Appoints Susan Kramer, Dr. P.H. Vice President of Project and Alliance Management
10/01/2009
XOMA Announces Initiation of Its Phase 2 Clinical Program for XOMA 052 in Type 2 Diabetes and Cardiovascular Disease
September
09/30/2009XOMA Announces $13.9 Million Financing
09/30/2009
XOMA Presents Results Demonstrating Novel Mechanism of Action for XOMA 052 in Regulating IL-1 Beta Levels
09/24/2009
XOMA Completes Full Repayment of Goldman Sachs Loan
09/23/2009
XOMA to Develop Therapeutic Antibody for H1N1 and H5N1 Influenza Viruses Under $2.2 Million U.S. Government Program Managed by SRI International
09/21/2009
XOMA Receives Anticipated Deficiency Notice From NASDAQ
09/14/2009
XOMA Announces Plan to Fully Repay Goldman Sachs Loan
09/09/2009
XOMA Announces $6 Million Antibody Discovery Collaboration With Arana Therapeutics
09/04/2009
XOMA to Present At Two Upcoming Investor Conferences
August
08/10/2009XOMA to Present At Canaccord Adams Global Growth Conference On August 12, 2009
08/06/2009
XOMA Reports 2009 Second Quarter Financial Results
08/03/2009
XOMA to Announce Second Quarter 2009 Financial Results and Host Conference Call on August 6
